Department of Cardiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
Nat Rev Cardiol. 2011 Oct 11;9(2):79-90. doi: 10.1038/nrcardio.2011.148.
The techniques and materials used during percutaneous coronary intervention have advanced considerably over the past 3 decades, yet restenosis remains one of the major drawbacks of this procedure. Many innovative technologies, including drug-eluting stents, with or without specific polymers, and fully biodegradable stents have been and continue to be developed in the search for a safe and effective antirestenosis therapy. Remarkable advances in stent design and nanoparticle delivery systems ('nanovehicles') have already fueled revolutionary changes in the prevention and treatment of in-stent restenosis. In this Review we provide an overview of the latest innovations for optimizing outcomes of coronary stenting, and up-to-date information about prevention and treatment of in-stent restenosis.
在过去的 30 年中，经皮冠状动脉介入治疗中使用的技术和材料已经有了很大的进步，但再狭窄仍然是该手术的主要缺点之一。许多创新技术，包括载药支架，无论是否使用特定的聚合物，以及完全可生物降解的支架，都已经并将继续被开发出来，以寻求一种安全有效的抗再狭窄治疗方法。支架设计和纳米颗粒输送系统（“纳米载体”）的显著进步已经推动了经皮冠状动脉介入治疗后再狭窄预防和治疗的革命性变化。在这篇综述中，我们概述了优化冠状动脉支架治疗效果的最新创新技术，并提供了有关经皮冠状动脉介入治疗后再狭窄预防和治疗的最新信息。
